Published in Vaccine on August 06, 2013
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology (1998) 4.13
Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol (1991) 3.83
Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature (1985) 3.62
NYVAC: a highly attenuated strain of vaccinia virus. Virology (1992) 3.38
Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology (1997) 3.17
[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B (1978) 2.92
Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med (2010) 2.61
[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr (1974) 2.50
A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine (1994) 2.22
Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol (1998) 2.06
ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense. Int J Infect Dis (2004) 1.70
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol (2004) 1.58
Preparation of cell cultures and vaccinia virus stocks. Curr Protoc Mol Biol (2001) 1.41
Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol (2006) 1.35
Generation of recombinant vaccinia viruses. Curr Protoc Mol Biol (2001) 1.30
Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen Virol (2007) 1.29
Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Arch Virol (1989) 1.26
MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther (2011) 1.24
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine (2009) 1.24
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16
Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One (2010) 1.15
Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology (1998) 1.15
New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine (2009) 1.12
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One (2011) 1.10
An avian cell line designed for production of highly attenuated viruses. Vaccine (2008) 1.07
Improved NYVAC-based vaccine vectors. PLoS One (2011) 1.04
Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol (2007) 1.02
Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One (2012) 1.01
Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara. Virus Res (2009) 1.00
Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One (2012) 0.96
Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One (2009) 0.90
Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice. Vaccine (2007) 0.89
Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol (2012) 0.87
Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines. J Gen Virol (2006) 0.86
Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells. Virology (2010) 0.84
[Virulence and immunogenicity of a modified vaccinia virus (strain MVA) (author's transl)]. Z Immunitatsforsch Exp Klin Immunol (1972) 0.83
Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice. J Virol (2011) 0.81
A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem (2003) 3.70
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host Microbe (2007) 2.97
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc Natl Acad Sci U S A (2002) 2.19
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Poxvirus multiprotein entry-fusion complex. Proc Natl Acad Sci U S A (2005) 2.09
Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol (2004) 2.06
Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol (2006) 1.94
Protein composition of the vaccinia virus mature virion. Virology (2006) 1.93
Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J Virol (2005) 1.88
Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J Virol (2005) 1.86
HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology (2006) 1.83
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol (2007) 1.77
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Discovery of antivirals against smallpox. Proc Natl Acad Sci U S A (2004) 1.76
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J Virol (2005) 1.73
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A (2010) 1.72
Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol (2002) 1.69
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr (2005) 1.68
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J Virol (2006) 1.63
Vaccinia virus A28L gene encodes an essential protein component of the virion membrane with intramolecular disulfide bonds formed by the viral cytoplasmic redox pathway. J Virol (2004) 1.62
Role of the I7 protein in proteolytic processing of vaccinia virus membrane and core components. J Virol (2004) 1.59
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
External scaffold of spherical immature poxvirus particles is made of protein trimers, forming a honeycomb lattice. J Cell Biol (2005) 1.55
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol (2003) 1.53
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology (2007) 1.52
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J Virol (2006) 1.45
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology (2002) 1.44
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A (2006) 1.44
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One (2010) 1.41
Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J Virol (2006) 1.40
Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex. J Virol (2007) 1.40
Vaccinia virus G7L protein Interacts with the A30L protein and is required for association of viral membranes with dense viroplasm to form immature virions. J Virol (2003) 1.39
Vaccinia virus l1 protein is required for cell entry and membrane fusion. J Virol (2008) 1.39
Vaccinia virus nonstructural protein encoded by the A11R gene is required for formation of the virion membrane. J Virol (2005) 1.39
Vaccinia virus D10 protein has mRNA decapping activity, providing a mechanism for control of host and viral gene expression. Proc Natl Acad Sci U S A (2007) 1.38
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother (2012) 1.32
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A (2008) 1.31
Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med (2007) 1.30
Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription. Proc Natl Acad Sci U S A (2003) 1.28
DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses (2004) 1.27
Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol (2009) 1.27
Vaccinia virus strain differences in cell attachment and entry. Virology (2009) 1.26
The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proc Natl Acad Sci U S A (2005) 1.24
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine (2009) 1.24
Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A (2002) 1.24
SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine (2011) 1.23
Existence of an operative pathway from the endoplasmic reticulum to the immature poxvirus membrane. Proc Natl Acad Sci U S A (2006) 1.23
Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression. J Virol (2006) 1.22
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J Virol (2009) 1.22
Characterization of a second vaccinia virus mRNA-decapping enzyme conserved in poxviruses. J Virol (2007) 1.22
Mapping interaction sites of the A20R protein component of the vaccinia virus DNA replication complex. Virology (2002) 1.21
Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology (2004) 1.21
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine (2007) 1.21
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. AIDS Res Hum Retroviruses (2004) 1.20
Expression profiling of the intermediate and late stages of poxvirus replication. J Virol (2011) 1.20
Genome-wide analysis of the 5' and 3' ends of vaccinia virus early mRNAs delineates regulatory sequences of annotated and anomalous transcripts. J Virol (2011) 1.19
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol (2007) 1.19
Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D. J Virol (2002) 1.18
Identification of second-site mutations that enhance release and spread of vaccinia virus. J Virol (2002) 1.16
Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology (2007) 1.16
Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses. J Virol (2009) 1.16
Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun (2013) 1.16
Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism. Cell Host Microbe (2012) 1.15
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis (2003) 1.15
Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry. Proc Natl Acad Sci U S A (2009) 1.15
Vaccinia virus G4L glutaredoxin is an essential intermediate of a cytoplasmic disulfide bond pathway required for virion assembly. J Virol (2002) 1.14
Murine norovirus infection has no significant effect on adaptive immunity to vaccinia virus or influenza A virus. J Virol (2009) 1.14